Kaiser Permanente Ventures and Samsung Next invested in the digital mental health treatment developer through a series B round that will fund product development and commercialisation.

Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.

Axa Venture Partners was among the limited partners that have helped the deep tech-focused venture firm raise $59.4m for its second fund.

Optum Ventures co-led a series B round that took the chronic disease management platform's total funding to $50m.

The pharmaceutical firm has transferred China-based business development director Manabu Aruga to its Tokyo headquarters where he will oversee corporate VC deals in Asia.

The universities of Edinburgh, Manchester, Glasgow and Aberdeen have all contributed to Epidarex’s latest fund, which will invest in life sciences spinouts.

Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Rutgers University-New Brunswick has spun out Infinity Biologix with backing from Viking Global Investors to manage the distribution of a saliva-based coronavirus test.

The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.